Estradiol
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Synonyms: D-Estradiol, D-Oestradiol, Estradiol-17beta, Estradiol Valerate, Estradiol Cypionate, Dihydroxyestrin, Dihydroxyoestrin, Dihydroxyesterin, Dihydrofollicular Hormone, Dihydrofolliculin, Cis-Estradiol, Cis-Oestradiol, Beta-Estradiol, estradiol, 17-beta.
Brand Names: Aerodiol, Agofollin, Alora, Altrad, Amnestrogen, Aquadiol, Bardiol, Climaderm, Climara, Combipatch, Compudose, Compudose 200, Compudose 365, Corpagen, Delestrogen, Depo-Estradiol, Dermestril, Dihydromenformon, Dihydrotheelin, Dimenformon, Dimenformon Prolongatum, Diogyn, Diogynets, Divigel, Encore, Esclim, Estinyl, Estrace, Estraderm, Estraderm Tts, Estradurin, Estrasorb, Estreva, Estrifam, Estring, Estring Vaginal Ring, Estroclim, Estroclim 50, Estrofem 2, Estrofem Forte, Estrogel, Estrogens, Esterified, Estrovite, Evorel, Extrasorb, Femestral, Femestrol, Feminone, Femogen, Fempatch, Femring, Femtrace, Femtran, Follicyclin, Ginedisc, Ginosedol, Gynergon, Gynestrel, Gynodiol, Gynoestryl, Gynpolar, Innofem, Lamdiol, Lynoral, Macrodiol, Macrol, Menest, Menorest, Menostar, Microdiol, Nordicol, Oestergon, Oestradiol, Oestradiol R, Oestrogel, Oestroglandol, Oestrogynal, Ovahormon, Ovasterol, Ovastevol, Ovociclina, Ovocyclin, Ovocycline, Ovocylin, Perlatanol, Primofol, Profoliol, Profoliol B, Progynon, Progynon Dh, Progynon-Dh, Ricifon, Ritsifon, Sandrena Gel, Sisare Gel, Sk-Estrogens, Soldep, Sotipox, Syndiol, Systen, Tradelia, Trial Sat, Trocosone, Vagifem, Vivelle, Zerella, Zumenon, Elestrin, Evamist.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Dosing and Administration
When estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Patients should be started at the lowest dose for the indication.
1. For treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible.
Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals. The usual initial dosage range is 1 to 2 mg daily of Estradiol adjusted as necessary to control presenting symptoms. The minimal effective dose for maintenance therapy should be determined by titration. Administration should be cyclic (e.g., 3 weeks on and 1 week off).
2. For treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
Treatment is usually initiated with a dose of 1 to 2 mg daily of Estradiol, adjusted as necessary to control presenting symptoms; the minimal effective dose for maintenance therapy should be determined by titration.
3. For treatment of breast cancer, for palliation only, in appropriately selected women and men with metastatic disease.
Suggested dosage is 10 mg three times daily for a period of at least three months.
4. For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only.
Suggested dosage is 1 to 2 mg three times daily. The effectiveness of therapy can be judged by phosphatase determinations as well as by symptomatic improvement of the patient.
5. For prevention of osteoporosis.
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should be considered only for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate.
The lowest effective dose of Estradiol has not been determined.
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Estradiol
Return to top
Publication Resources
Most Recent Articles on Estradiol
Review Articles on Estradiol
Articles on Estradiol in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Estradiol
Return to top
Trial Resources
Ongoing Trials with Estradiol at Clinical Trials.gov
Trial Results with Estradiol
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Estradiol
Cochrane Collaboration on Estradiol
Cost Effectiveness of Estradiol
Return to top
Media Resources
Powerpoint Slides on Estradiol
Images of Estradiol
Podcasts & MP3s on Estradiol
Videos on Estradiol
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Estradiol
Discussion Groups on Estradiol
Patient Handouts on Estradiol
Blogs on Estradiol
Estradiol in the News
Estradiol in the Marketplace
Return to top
International Resources
Estradiol en Español
Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
